Clinical Trial Update: Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

View source ↗

Summary

A multicenter prospective study is validating a universal assay to quantify levels of apixaban, rivaroxaban, danaparoid, and fondaparinux.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)
• Danaparoid (danaparoid)
• Fondaparinux (fondaparinux)
• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Nantes University Hospital | Conditions: Anticoagulation, Venous Thromboembolism | Status: RECRUITING